Stockreport

CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024 [Yahoo! Finance]

CYTODYN INC  (CYDY) 
NASDAQ:AMEX Investor Relations: ir.cytodyn.com
PDF leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC Laboratories, Inc. (“SMC” [Read more]